Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6379566 | 0.91 | JAK2 (0.57) | JAK2JAK3 | |
| SCHEMBL3224390 | 0.85 | CHEK1 (0.50) | JAK2JAK3 | |
| SCHEMBL16245120 | 0.81 | JAK3 (0.81) | JAK2JAK3 | |
| SCHEMBL17160154 | 0.81 | JAK2 (0.55) | JAK2JAK3 | |
| SCHEMBL21678729 | 0.81 | CHEK1 (0.45) | JAK2JAK3 | |
| SCHEMBL15032693 | 0.80 | JAK3 (0.77) | JAK2JAK3 | |
| SCHEMBL30585856 | 0.80 | JAK2 (0.59) | JAK2JAK3 | |
| SCHEMBL9937764 | 0.80 | JAK3 (0.57) | JAK2JAK3 | |
| SCHEMBL12777831 | 0.79 | MAP3K7 (0.56) | JAK2JAK3 | |
| SCHEMBL15032680 | 0.78 | JAK3 (1.00) | JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035373-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ACLARIS THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12297203-B2 | Pyrrolopyrimidine ITK inhibitors | ACLARIS THERAPEUTICS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| CN-119080779-A | Pyrrolopyrimidine ITK inhibitors | 阿克拉瑞斯治疗股份有限公司 | 2024-12-06 | — | — | CN | disclosed |
| CN-112823005-B | Pyrrolopyrimidine ITK inhibitors | 阿克拉瑞斯治疗股份有限公司 | 2024-08-20 | — | — | CN | disclosed |
| US-20240132505-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ACLARIS THERAPEUTICS, INC. | 2024-04-25 | — | — | US | disclosed |
| US-11820775-B2 | Pyrrolopyrimidine ITK inhibitors | ACLARIS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820775-B2 | Pyrrolopyrimidine ITK inhibitors | ACLARIS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820775-B2 | Pyrrolopyrimidine ITK inhibitors | ACLARIS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20220348579-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ACLARIS THERAPEUTICS, INC. | 2022-11-03 | — | — | US | disclosed |
| US-11021482-B2 | Pyrrolopyrimidine ITK inhibitors | Adaris Therapeutics, Inc. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
| EP-2390254-A1 | NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-11-30 | — | — | EP | disclosed |
| EP-2390254-A1 | NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-11-30 | — | — | EP | disclosed |
| US-20110257678-A1 | VASCULAR EMBOLIC FILTER EXCHANGE DEVICES AND METHODS OF USE THEREOF | INCEPT LLC (US) | 2011-10-20 | — | — | US | disclosed |
| EP-0496617-B1 | Adenosine kinase inhibitors | METABASIS THERAPEUTICS INC (US) | 1999-12-01 | — | — | EP | disclosed |
| US-5646128-A | TREATING INFLAMMATION, SEPSIS, SEPTIC SHOCK, BURNS | GENSIA, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1992012718-A1 | ADENOSINE KINASE INHIBITORS | GENSIA, INC. (US) | 1992-08-06 | — | — | WO | disclosed |
| EP-0496617-A1 | Adenosine kinase inhibitors | GENSIA, INC. (US) | 1992-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035373-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | JAK3, JAK1, JAK2 | JAK2 3/4885JAK3 1/4885 |
| US-20240132505-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ITK, PDXK, DMPK | JAK2 576/4885JAK3 1484/4885 |
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | GPR119, GPR139, HCAR1 | JAK2 1199/4885JAK3 2666/4885 |
| US-12297203-B2 | Pyrrolopyrimidine ITK inhibitors | ITK, PDXK, DMPK | JAK2 576/4885JAK3 1484/4885 |
| US-20220348579-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ITK, PDXK, DMPK | JAK2 576/4885JAK3 1484/4885 |
| US-11021482-B2 | Pyrrolopyrimidine ITK inhibitors | ITK, PDXK, DMPK | JAK2 576/4885JAK3 1484/4885 |
| US-11820775-B2 | Pyrrolopyrimidine ITK inhibitors | ITK, PDXK, DMPK | JAK2 576/4885JAK3 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.